Anti-VEGF Innovations in Retinal Disease
Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.
A recent Ophthalmology Times Case-Based Roundtable discussed the structural differences among newer second-generation anti-VEGF agents and their implications for clinical efficacy and treatment durability.
The discussion highlighted real-world experiences and evidence regarding extended treatment intervals and sustained disease control with these newer therapies.
Stewart, MD, summarized the key takeaways from the discussion.
He presented a case of an 83-year-old woman with diabetic macular edema (DME) who underwent temporal grid laser photocoagulation and received bevacizumab intravitreal injections every 4 to 6 weeks.
Author's summary: Emerging anti-VEGF agents improve retinal disease treatment.
More News
- 10 great erotic horror films
- NewJeans loses Ador court battle to leave agency
- How Discrimination and Stress Impact the Mental Health of Young Sexual Minority Men
- Tomago’s slow death exposes folly of ‘Made in Australia’ dream
- Can Hollywood Get Veterans Right—and Could It Actually Save Lives?
- Eala falls to Mboko to exit Hong Kong Open
- Emmy-Winner Chronicles Yankees Icon Joe Torre’s MLB Legacy On Screen
- Marcus Sack: Smart growth is here, once you see it
- The Weekend Scene: Celebrate Halloween, Day of the Dead and more in the DC area
- Building a stable ‘abode of thought’: Kant’s rules for virtuous thinking